Virtual vs Physical Screening in Drug Discovery

The comparison between virtual screening and physical screening has become a central topic in modern drug discovery, as laboratories seek to balance efficiency and certainty.

Advances in computational power, structural biology, and data availability have expanded the role of in silico drug discovery, while physical, or experimental, high-throughput screening (HTS) remains a cornerstone of validation. Understanding how these approaches differ—and how they complement one another—is essential to balancing speed, cost, and experimental rigor in screening pipelines.

This article examines the principles, workflows, and performance characteristics of virtual and physical screening, with a focus on how laboratory scientists can move away from debating virtual vs physical screening and instead combine strategies to improve hit identification and lead optimization.

Principles of virtual screening in in silico drug discovery

Virtual screening refers to the computational evaluation of large compound libraries to identify molecules likely to interact with a biological target.

These workflows operate upstream of wet-lab experimentation and physical screening, enabling prioritization of compounds for synthesis or testing based on predicted activity.

Virtual screening methods generally fall into three categories:

• Structure-based virtual screening (SBVS): Relies on three-dimensional target structures and uses molecular docking to predict ligand–target binding strength across multiple orientations.
• Ligand-based virtual screening (LBVS): Operates without explicit target structures, so is useful when three-dimensional structures of target proteins are either unavailable or unreliable. This approach identifies compounds based on chemical similarity to known active compounds.
• Hybrid methods: LBVS is used first to pre-filter large compound libraries. Compounds with predicted activity are then docked against the protein structure in SBVS. The combination of the two approaches increases the chance of identifying drug candidates.

Following virtual screening, compounds are ranked, typically according to four key scoring functions:

1. Force-field-based scoring, which estimates binding affinity by calculating physical interactions between molecules, such as van der Waals interactions.
2. Empirical scoring, which also estimates binding affinity, but using weighted interaction terms calibrated against experimentally measured binding data.
3. Knowledge-based scoring, derived from statistical analyses of intermolecular contacts.
4. Machine learning (ML)-based scoring, which uses AI models to predict binding affinity.

Once scores are produced, properties such as drug-likeness are carefully considered. Next, the top‑ranking and most plausible compounds undergo post-processing steps before advancing to experimental validation.

Workflows are increasingly leveraging the power of ML models trained on experimental bioactivity data to rank compounds. Implementing AI within virtual screening workflows has shown significant benefits, including increased screening speed, reduced cost per screen, and increased hit-to-lead success.

These considerations frame the ongoing discussion around virtual screening vs physical screening in modern drug discovery.

Advantages and limitations of virtual screening methods

Virtual screening offers significant advantages. It enables the evaluation of millions of compounds in days rather than months, increasing efficiency. Additionally, computational costs scale more favorably than experimental testing.

However, virtual screening generates hypotheses, rather than definitive hits. Predictive accuracy depends on the quality of the input data and the selection of appropriate simulation models. Inaccurate target models, or insufficient libraries and methods, can result in false positives or false negatives. This means promising active compounds could be missed, while poor compounds are prioritized.

Physical screening and high-throughput experimental workflows

Physical screening, most commonly implemented as HTS, involves the experimental testing of compounds against a biological assay. This approach directly measures biochemical or cellular responses, providing empirical evidence of activity.

Key features of physical screening include:

• Types of assays: Cell-free biochemical assays and cell-based assays.
• Throughput: Tens of thousands to over a million compounds per campaign using automated liquid handling and detection systems.
• Readouts: Fluorescence, luminescence, absorbance, or label-free technologies.

HTS remains essential for targets lacking reliable structural data or for phenotypic discovery, where the mechanism of action may be unknown at the outset.

Constraints in physical screening

Physical screening requires substantial investment in reagents, instrumentation, and management of large compound collections. Assay interference, false positives, and false negatives remain persistent challenges. As a result, many laboratories now restrict full HTS campaigns to smaller, pre-filtered libraries informed by computational prioritization.

Accelerate your PROTACs drug discovery and development

This eBook shows how an integrated, end-to-end analytical approach helps labs generate reliable, regulatory-ready PROTAC data at every stage of development.
View eBook

Advertisement

Virtual screening vs physical screening: comparing HTS approaches

In HTS, virtual screening excels at rapid hypothesis generation, while physical screening provides biologically grounded data that can underpin decisions on progression.

A direct comparison of virtual screening vs physical screening highlights how the two approaches differ across specific parameters (Table 1).

Table 1: Comparing key parameters in virtual screening vs physical screening.

Virtual screening vs physical screening: complementary roles

Researchers do not need to choose between computational and experimental screening, but can instead use them together to yield optimal efficiency across drug discovery stages. Integrating AI and ML with physical screening pipelines increasingly follows a defined set of stages: computational triage, focused experimental screening, and iterative refinement (Figure 1).

Figure 1: An infographic showing a three‑stage drug discovery workflow: computational triage, focused experimental screening, and iterative refinement. Credit: AI-generated image created using Google Gemini (2026).

In this process, virtual screening is used to reduce the library size based on predicted outcomes. Selected subsets of compounds then undergo biochemical or cellular assays, and experimental data feeds back into computational models to improve predictions.

This cyclical approach improves hit rates and reduces late-stage attrition. It also aligns with laboratory capacity constraints by reserving complex assays for the most promising compounds.

Tech Spotlight: High-Throughput Screening 2026

Explore reliable high-throughput screening workflows for vaccine and antibody discovery, covering assay design, validation and data analysis to improve reproducibility, data quality and candidate prioritization.

View Webinar

Advertisement

With ML, active learning frameworks adapt screening strategies in real time, using early assay results to guide subsequent compound selection.

Data integrity and translational considerations

Both screening strategies introduce distinct data quality considerations. Virtual screening outputs depend heavily on algorithmic assumptions, while physical screening data reflect assay design, detection limits, and biological context.

Key translational factors include:

• Reproducibility: Experimental hits require confirmation across orthogonal assays.
• Chemical feasibility: Virtual hits may be synthetically infeasible or unstable.
• Biological relevance: Phenotypic screens may reveal actionable biology absent from target-based models, such as those predicted in computational screening.

Laboratories increasingly assess screening outcomes through integrated data management systems, enabling cross-validation between predicted and observed activity.

Using virtual screening and physical screening in modern drug discovery

Today, the comparison of virtual screening vs physical screening reflects a broader shift toward integrated workflows.

The growing, combined use of the two approaches reflects an evolution in how drug discovery laboratories need to manage increasing complexity, scale, and uncertainty. While virtual screening accelerates early-stage exploration, physical screening anchors discovery decisions in experimental biology. Today, the most effective discovery strategies combine both approaches in iterative, data-driven workflows.

As computational models improve and experimental platforms become more adaptive, the distinction between in silico drug discovery and laboratory screening continues to narrow. For research organizations, the strategic integration of these technologies directly shapes productivity, cost efficiency, and translational success.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.